The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

garretda

Forum Replies Created

Viewing 2 reply threads
  • Replies
      garretda
      Participant

        Approximately 7 months on pembrolizumab and imatinib –  fatigue has been the most noticeable side effect.  Pruritus, itchy skin, was also an issue initially, but has appeared to subside somewhat.

        garretda
        Participant

          Approximately 7 months on pembrolizumab and imatinib –  fatigue has been the most noticeable side effect.  Pruritus, itchy skin, was also an issue initially, but has appeared to subside somewhat.

          garretda
          Participant

            Approximately 7 months on pembrolizumab and imatinib –  fatigue has been the most noticeable side effect.  Pruritus, itchy skin, was also an issue initially, but has appeared to subside somewhat.

        Viewing 2 reply threads
        About the MRF Patient Forum

        The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

        The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

        Popular Topics